Get the Stockscreener App
7.72
1.44%
0.08
Gyre Therapeutics Inc stock is traded at $7.72, with a volume of 42,523.
It is up +1.44% in the last 24 hours and up +4.45% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$7.64
Open:
$7.72
24h Volume:
42,523
Relative Volume:
0.20
Market Cap:
$726.62M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
82.57
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+9.15%
1M Performance:
+4.45%
6M Performance:
-33.99%
1Y Performance:
-48.40%
1-Day Range:
$7.55
$7.7931
1-Week Range:
$7.10
$7.7931
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.75 | 692.62M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.07 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.18 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.90 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.29 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.75 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Gyre Therapeutics Inc. stock trend outlook and recovery pathHistorical Market Behavior and Trend Summary - Newser
Using Python tools to backtest Gyre Therapeutics Inc. strategiesLow-Risk Reversal Pattern Analysis Tracker - Newser
How volatile is Gyre Therapeutics Inc. stock compared to the marketAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
When is the best time to exit Gyre Therapeutics Inc.Free Daily Profit Focused Stock Screener - Newser
What makes Gyre Therapeutics Inc. stock price move sharply Short-Term Trade Setup with Forecast Insight - Newser
How hedge fund analytics apply to Gyre Therapeutics Inc. stock Short-Term Sector Movement Forecast Generator - Newser
Price momentum metrics for Gyre Therapeutics Inc. explained Equity Portfolio Outlook and Performance Summary - Newser
Should I hold or sell Gyre Therapeutics Inc. stock in 2025Capitalize on proven investment strategies - jammulinksnews.com
What are the technical indicators suggesting about Gyre Therapeutics Inc.Maximize your portfolio’s growth with expert tips - jammulinksnews.com
Is Gyre Therapeutics Inc. stock overvalued or undervaluedUnlock daily market insights for better trades - jammulinksnews.com
What is Gyre Therapeutics Inc. company’s growth strategyGet alerts on high-potential stock breakouts - jammulinksnews.com
What are Gyre Therapeutics Inc. company’s key revenue driversUnlock powerful market trend analysis - jammulinksnews.com
What catalysts could drive Gyre Therapeutics Inc. stock higher in 2025Free Stock Market Beginners Guide - jammulinksnews.com
Gyre Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingHigh Win Rate Stock Ideas - Newser
Why MDGL stock attracts strong analyst attentionFree Access to Community with 300% Return - Newser
What are the latest earnings results for Gyre Therapeutics Inc.Consistently outstanding ROI - jammulinksnews.com
What drives Gyre Therapeutics Inc. stock priceExtraordinary performance - PrintWeekIndia
Is Gyre Therapeutics Inc. stock a growth or value playRapidly expanding wealth - jammulinksnews.com
What analysts say about Gyre Therapeutics Inc. stockFastest return on investment - PrintWeekIndia
Will Gyre Therapeutics Inc. stock benefit from AI tech trendsEarly Breakout Tracker - Newser
What makes Gyre Therapeutics Inc. stock price move sharplyMulti Bagger Alerts - Newser
Why Gyre Therapeutics Inc. stock attracts strong analyst attentionLow Volatility High Yield Stocks - Newser
Is Gyre Therapeutics Inc. a good long term investmentMarket-crushing profits - jammulinksnews.com
Gyre Therapeutics Inc. Stock Analysis and ForecastHigh-yield capital appreciation - jammulinksnews.com
Is GEOS a good long term investmentStrong return on assets - Autocar Professional
What drives LVRO stock priceFree Consultation - jammulinksnews.com
What drives UWMC.WS stock priceSuperior investment outcomes - jammulinksnews.com
Best Stocks for Dividend Growth in India Trusted Investment GroupFree Market Dynamics Reports - Autocar Professional
Stocks with the Best Technical Indicators in India Intelligent Investment DecisionsExceptional earning trajectories - PrintWeekIndia
Is LCUT a good long term investmentRemarkably fast returns - PrintWeekIndia
Can Confidence Petroleum India Limited (526829) Maintain Its ValuationFree Stock Market Beginners Guide - PrintWeekIndia
What drives Delta Air Lines Inc. stock priceHigh-velocity capital appreciation - Autocar Professional
D India Limited (522275) Sees Unusual Trading VolumeSuperior returns - jammulinksnews.com
Best Real Estate Stocks AI Driven Market StrategiesFree Consultation - jammulinksnews.com
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
0.49%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):